<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-archivearticle1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4608737</article-id><article-id pub-id-type="pmid">26473596</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0140883</article-id><article-id pub-id-type="publisher-id">PONE-D-15-23833</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>Maintenance of Chronic Fatigue Syndrome (CFS) in Young CFS Patients Is Associated with the 5-HTTLPR and SNP rs25531 A &gt; G Genotype </plain></SENT>
</text></SecTag></article-title><alt-title alt-title-type="running-head">Chronic Fatigue Syndrome and 5-HTT Genotype</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Meyer</surname><given-names>Benedicte</given-names></name><xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Nguyen</surname><given-names>Chinh Bkrong Thuy</given-names></name><xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Moen</surname><given-names>Aurora</given-names></name><xref ref-type="aff" rid="aff002">
<sup>2</sup>
</xref><xref ref-type="aff" rid="aff007">
<sup>7</sup>
</xref><xref ref-type="aff" rid="aff009">
<sup>9</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Fagermoen</surname><given-names>Even</given-names></name><xref ref-type="aff" rid="aff003">
<sup>3</sup>
</xref><xref ref-type="aff" rid="aff006">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Sulheim</surname><given-names>Dag</given-names></name><xref ref-type="aff" rid="aff004">
<sup>4</sup>
</xref><xref ref-type="aff" rid="aff005">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Nilsen</surname><given-names>Hilde</given-names></name><xref ref-type="aff" rid="aff006">
<sup>6</sup>
</xref><xref ref-type="aff" rid="aff008">
<sup>8</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Wyller</surname><given-names>Vegard Bruun</given-names></name><xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref><xref ref-type="aff" rid="aff006">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Gjerstad</surname><given-names>Johannes</given-names></name><xref ref-type="aff" rid="aff002">
<sup>2</sup>
</xref><xref ref-type="aff" rid="aff007">
<sup>7</sup>
</xref><xref ref-type="aff" rid="aff009">
<sup>9</sup>
</xref><xref rid="cor001" ref-type="corresp">*</xref></contrib></contrib-group><aff id="aff001">
<label>1</label>
<addr-line>Dept. of Paediatrics, Akershus University Hospital, Oslo, Norway</addr-line>
</aff><aff id="aff002">
<label>2</label>
<addr-line>Dept. of Physical Medicine and Rehabilitation, Oslo University Hospital, Oslo, Norway</addr-line>
</aff><aff id="aff003">
<label>3</label>
<addr-line>Dept. of Anaesthesiology and Critical Care, Oslo University Hospital, Oslo, Norway</addr-line>
</aff><aff id="aff004">
<label>4</label>
<addr-line>Dept. of Paediatrics, Lillehammer County Hospital, Lillehammer, Norway</addr-line>
</aff><aff id="aff005">
<label>5</label>
<addr-line>Dept. of Paediatrics, Oslo University Hospital, Oslo, Norway</addr-line>
</aff><aff id="aff006">
<label>6</label>
<addr-line>Institute of Clinical Medicine, Medical Faculty, University of Oslo, Oslo, Norway</addr-line>
</aff><aff id="aff007">
<label>7</label>
<addr-line>National Institute of Occupational Health, Oslo, Norway</addr-line>
</aff><aff id="aff008">
<label>8</label>
<addr-line>Section for Clinical Molecular Biology, Akershus University Hospital, Oslo, Norway</addr-line>
</aff><aff id="aff009">
<label>9</label>
<addr-line>Department of Biosciences, University of Oslo, Oslo, Norway</addr-line>
</aff><contrib-group><contrib contrib-type="editor"><name><surname>Nater</surname><given-names>Urs M</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">
<addr-line>University of Marburg, GERMANY</addr-line>
</aff><author-notes><fn fn-type="COI-statement" id="coi001"><p><text><SENT sid="1" pm="."><plain>Competing Interests: The authors have declared that no competing interests exist. </plain></SENT>
</text></p></fn><fn fn-type="con" id="contrib001"><p><text><SENT sid="2" pm="."><plain>Conceived and designed the experiments: BM AM VBW HN JG. </plain></SENT>
<SENT sid="3" pm="."><plain>Performed the experiments: BM CBTN AM EF DS HN VBW JG. </plain></SENT>
<SENT sid="4" pm="."><plain>Analyzed the data: BM CBTN AM HN VBW JG. </plain></SENT>
<SENT sid="5" pm="."><plain>Contributed reagents/materials/analysis tools: CBTN AM JG. </plain></SENT>
<SENT sid="6" pm="."><plain>Wrote the paper: BM CBTN AM HN VBW JG. </plain></SENT>
</text></p></fn><corresp id="cor001">* E-mail: <email>johannes.gjerstad@stami.no</email></corresp></author-notes><pub-date pub-type="epub"><day>16</day><month>10</month><year>2015</year></pub-date><pub-date pub-type="collection"><year>2015</year></pub-date><volume>10</volume><issue>10</issue><elocation-id>e0140883</elocation-id><history><date date-type="received"><day>3</day><month>6</month><year>2015</year></date><date date-type="accepted"><day>30</day><month>9</month><year>2015</year></date></history><permissions><copyright-statement>© 2015 Meyer et al</copyright-statement><copyright-year>2015</copyright-year><copyright-holder>Meyer et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="pone.0140883.pdf"/><abstract><p><SecTag type="ABS"><text><SENT sid="7" pm="."><plain>Earlier studies have shown that genetic variability in the SLC6A4 gene encoding the serotonin transporter (5-HTT) may be important for the re-uptake of serotonin (5-HT) in the central nervous system. </plain></SENT>
<SENT sid="8" pm="."><plain>In the present study we investigated how the 5-HTT genotype i.e. the short (S) versus long (L) 5-HTTLPR allele and the SNP rs25531 A &gt; G affect the physical and psychosocial functioning in patients with chronic fatigue syndrome (CFS). </plain></SENT>
<SENT sid="9" pm="."><plain>All 120 patients were recruited from The Department of Paediatrics at Oslo University Hospital, Norway, a national referral center for young CFS patients (12–18 years). </plain></SENT>
<SENT sid="10" pm="."><plain>Main outcomes were number of steps per day obtained by an accelerometer and disability scored by the Functional Disability Inventory (FDI). </plain></SENT>
<SENT sid="11" pm="."><plain>Patients with the 5-HTT SS or SLG genotype had a significantly lower number of steps per day than patients with the 5-HTT LALG, SLA or LALA genotype. </plain></SENT>
<SENT sid="12" pm="."><plain>Patients with the 5-HTT SS or SLG genotype also had a significantly higher FDI score than patients with the 5-HTT LALG, SLA or LALA genotype. </plain></SENT>
<SENT sid="13" pm="."><plain>Thus, CFS patients with the 5-HTT SS or SLG genotype had worse 30 weeks outcome than CFS patients with the 5-HTT LALG, SLA or LALA genotype. </plain></SENT>
<SENT sid="14" pm="."><plain>The present study suggests that the 5-HTT genotype may be a factor that contributes to maintenance of CFS. </plain></SENT>
</text></SecTag></p></abstract><funding-group><funding-statement>The study was supported by the Health Authority South-East Norway.</funding-statement></funding-group><counts><fig-count count="3"/><table-count count="3"/><page-count count="11"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>Due to ethical restrictions, anonymized data are available by request. To request access, please contact Director of Communication Sture Bye at the National Institute of Occupational Health (NIOH), Norway (<email>postmottak@stami.no</email>).</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>Due to ethical restrictions, anonymized data are available by request. To request access, please contact Director of Communication Sture Bye at the National Institute of Occupational Health (NIOH), Norway (<email>postmottak@stami.no</email>).</p></notes></front><body><SecTag type="INTRO"><sec sec-type="intro" id="sec001"><title><text><SENT sid="15" pm="."><plain>Introduction </plain></SENT>
</text></title><p><text><SENT sid="16" pm="."><plain>Chronic fatigue syndrome (CFS) is a long lasting debilitating disorder, characterized by symptoms like disabling fatigue, cognitive impairments, pain and orthostatic intolerance [1]. </plain></SENT>
<SENT sid="17" pm="."><plain>The diagnosis is based on clinical criteria, and exclusion of other somatic disorder and psychiatric diagnosis. </plain></SENT>
<SENT sid="18" pm="."><plain>In adolescents, CFS is associated with reduced physical and psychosocial functioning and may be an underlying cause of school drop-out and later workplace absenteeism. </plain></SENT>
<SENT sid="19" pm="."><plain>Among individuals between 8–17 years the lifetime prevalence of CFS is about 1% [2]. </plain></SENT>
</text></p><p><text><SENT sid="20" pm="."><plain>Earlier studies suggest that CFS may be associated with genetic variability in genes important for serotonin (5-HT) signaling [3,4]. </plain></SENT>
<SENT sid="21" pm="."><plain>Therefore, genetic variability that influences the function of the 5-HT transporter (5-HTT) in the brain might be of importance. </plain></SENT>
<SENT sid="22" pm="."><plain>Several genetic variants affect the 5-HTT expression that controls the 5-HT re-uptake. </plain></SENT>
<SENT sid="23" pm="."><plain>One of these is the 5-HTT promoter repeated-length polymorphic region (LPR) [5]. </plain></SENT>
<SENT sid="24" pm="."><plain>This repeated-length region consists of 22 base pairs (bp). </plain></SENT>
<SENT sid="25" pm="."><plain>Two common allelic variants have been described, a short (S) allele of 14 repeats and a long (L) allele of 16 repeats [6]. </plain></SENT>
<SENT sid="26" pm="."><plain>The S allele seems to reduce the transcription rate and lower expression of the transporter in cell membranes [7,8]. </plain></SENT>
</text></p><p><text><SENT sid="27" pm="."><plain>In the gene encoding the 5-HTT there is also a single nucleotide polymorphism (SNP), an A to G substitution rs25531 in the promoter [5]. </plain></SENT>
<SENT sid="28" pm="."><plain>This A to G shift creates a possible binding site for a transcription factor, activating enhancer-binding protein 2 (AP2) [5]. </plain></SENT>
<SENT sid="29" pm="."><plain>AP2 is a transcription inhibitor found to bind to the sequence if the G substitution is present [9]. </plain></SENT>
<SENT sid="30" pm="."><plain>Therefore both the S allele of 14 repeats, and the SNP that introduces the A to G substitution rs25531 (G), may reduce the transcription rate of the 5-HTT gene SLC6A4 in neuronal tissues. </plain></SENT>
<SENT sid="31" pm="."><plain>The G allele has, however, a low frequency, and seems to be present only on the L alleles of 16 repeats. </plain></SENT>
</text></p><p><text><SENT sid="32" pm="."><plain>Earlier studies have suggested that negative psychosocial stressors may have a more pronounced impact on individuals with the 5-HTT SS and SLG genotype than other individuals [10]. </plain></SENT>
<SENT sid="33" pm="."><plain>Moreover, variation in the 5-HTT gene SLC6A4, indicating decreased transcription, may modulate anxiety and negative affect [11,12]. </plain></SENT>
<SENT sid="34" pm="."><plain>However, individuals with the low 5-HTT transcription genotype also seem to have a more pronounced effect of positive environmental factors. </plain></SENT>
<SENT sid="35" pm="."><plain>Therefore, it seems likely that the low 5-HTT transcription genotype is associated with increased neuroplasticity making individuals more susceptible to environmental influences [13]. </plain></SENT>
</text></p><p><text><SENT sid="36" pm="."><plain>Difficulty with performance of daily activities (in home, school and social domains) may be associated with anxiety. </plain></SENT>
<SENT sid="37" pm="."><plain>Based on the link between anxiety and the 5-HTT SS and SLG genotype [12], we hypothesized that CFS patients with this genotype, would have a more pronounced reduction in the daily activities than other CFS patients. </plain></SENT>
<SENT sid="38" pm="."><plain>Hence, daily activity and disability were defined as main outcomes in the present study. </plain></SENT>
<SENT sid="39" pm="."><plain>The aim of the present study was to examine how the 5-HTTLPR and SNP rs25531 A &gt; G genotype influences physical and psychosocial functioning in CFS patients. </plain></SENT>
</text></p></sec></SecTag><SecTag type="METHODS"><sec sec-type="materials|methods" id="sec002"><title><text><SENT sid="40" pm="."><plain>Materials and Methods </plain></SENT>
</text></title><sec id="sec003"><title><text><SENT sid="41" pm="."><plain>Subjects </plain></SENT>
</text></title><p><text><SENT sid="42" pm="."><plain>The present study was a part of the NorCAPITAL-project (The Norwegian Study of Chronic Fatigue Syndrome in Adolescents: Pathophysiology and Intervention Trial). </plain></SENT>
<SENT sid="43" pm="."><plain>As previously described [14], all patients were recruited from The Department of Paediatrics at Oslo University Hospital, Norway, a national referral center for young CFS patients (12–18 years). </plain></SENT>
<SENT sid="44" pm="."><plain>The intervention used in the trial was orally administered clonidine (25 μg or 50 μg for body weight &lt;35 kg or &gt;35 kg, respectively, twice daily). </plain></SENT>
<SENT sid="45" pm="."><plain>Since the double-blinded clonidine intervention did not have any effect on the physical and psychosocial functioning in the patients [14], the clonidine treatment was only considered as a potential co-factor. </plain></SENT>
<SENT sid="46" pm="."><plain>A broad case definition of CFS, requiring three or more months of unexplained, disabling fatigue worsened by physical or mental exertion, was applied [15]. </plain></SENT>
</text></p><p><text><SENT sid="47" pm="."><plain>Data were collected in the period March 2010 until October 2012. </plain></SENT>
<SENT sid="48" pm="."><plain>Written, informed consent was obtained from all the participants and their parents. </plain></SENT>
<SENT sid="49" pm="."><plain>The project was approved by the Norwegian National Committee for Ethics in Medical Research and the Norwegian Medicines Agency. </plain></SENT>
<SENT sid="50" pm="."><plain>A total of 176 patients (all Caucasian) with CFS were assessed for eligibility, of which 120 fulfilled the inclusion criteria, started treatment at the hospital and were included in the present study (for further information, see Sulheim et al 2014 [14]). </plain></SENT>
<SENT sid="51" pm="."><plain>In addition, 38 age and gender balanced healthy controls from the same geographical area served as a reference group. </plain></SENT>
</text></p><p><text><SENT sid="52" pm="."><plain>At inclusion the data set of the 120 patients was 100% complete. </plain></SENT>
<SENT sid="53" pm="."><plain>However, 14 patients became drop-outs between inclusion and 8 weeks and another 5 patients became drop-outs between 8 weeks and 30 weeks. </plain></SENT>
<SENT sid="54" pm="."><plain>The total number of drop-outs during the follow-up was therefore 19 patients i.e. 16%. </plain></SENT>
<SENT sid="55" pm="."><plain>The number of patients at 30 weeks was 101. </plain></SENT>
</text></p></sec><sec id="sec004"><title><text><SENT sid="56" pm="."><plain>Clinical measures </plain></SENT>
</text></title><p><text><SENT sid="57" pm="."><plain>In the present study we focused on two main outcomes; daily activity and disability. </plain></SENT>
<SENT sid="58" pm="."><plain>Daily activity were measured by mean number of steps per day (number of steps), obtained by an accelerometer. </plain></SENT>
<SENT sid="59" pm="."><plain>Such accelerometers provide reliable data among patients with impaired physical capacity [16]. </plain></SENT>
<SENT sid="60" pm="."><plain>According to present recommendations, a recording period of seven consecutive days was used [17]. </plain></SENT>
<SENT sid="61" pm="."><plain>The participants were instructed to wear the unit permanently (i.e. also during the night). </plain></SENT>
<SENT sid="62" pm="."><plain>Moreover, the questionnaire Functional Disability Inventory (FDI) was used to measure disability. </plain></SENT>
<SENT sid="63" pm="."><plain>The FDI is a 15-item self-report inventory assessing difficulty with the performance of daily activities (in home, school and social domains) such as “doing chores at home,” “being at school all day,” or “walking the length of a football field.” Items were rated on a 5-point Likert scale, ranging from 0 to 4 (“No Trouble” to “Impossible”) and summed to create a total score (range 0–60) with higher scores indicating greater pain-related disability. </plain></SENT>
<SENT sid="64" pm="."><plain>The FDI score may be considered as a global measure of children’s and adolescent’s physical and psychosocial functioning in everyday social roles [18]. </plain></SENT>
</text></p></sec><sec id="sec005"><title><text><SENT sid="65" pm="."><plain>qPCR </plain></SENT>
</text></title><p><text><SENT sid="66" pm="."><plain>The blood samples (3ml; antecubital venous puncture at 30 weeks, 101 patients), were collected in Tempus Blood RNA Tubes (for further information, see Sulheim et al 2014 [14]). </plain></SENT>
<SENT sid="67" pm="."><plain>Total RNA was extracted by Tempus spin RNA isolation Reagent kit (4378926, Life Technologies/Applied Biosystems), and (for 92 patients; those with RIN&gt;7) converted into cDNA by High-Capacity cDNA Reverse Transcription Kit (4374966, Life technology). </plain></SENT>
<SENT sid="68" pm="."><plain>Primers were designed based on Ensembl transcript ENST00000261707 sequence and OligoEvaluator Tools (Sigma Aldrich), and checked for specificity by performing a BLAST search. </plain></SENT>
<SENT sid="69" pm="."><plain>To avoid amplification of possible genomic DNA contamination, PCR primers were designed to span a boundary region of two continuous exons. </plain></SENT>
<SENT sid="70" pm="."><plain>The gene expression of the target gene 5-HTT was normalized to the expression of the reference gene GAPDH. </plain></SENT>
<SENT sid="71" pm="."><plain>The primer sequences were: 5-HTT forward; AACTG CTACC AAGAT GCCCT, 5-HTT reverse; CTCAG CCATG TAACC GAGCA, GAPDH forward; CCAAC TGCTTA GCACC CCT and GAPDH reverse; TGGCA TGGAC TGTGG TCAT. </plain></SENT>
<SENT sid="72" pm="."><plain>The quantitative PCR analysis was performed on an ABI 7900 HT (Applied Biosystems, Foster City, California, USA), 40 cycles x (95°C 5s, 60°C 15s), using the Evagreen Sso Fast Master mix (Biorad Laboratories, CA-USA); 05μM primer mix; 2μl cDNA in a total reaction volume of 10 μL. </plain></SENT>
</text></p></sec><sec id="sec006"><title><text><SENT sid="73" pm="."><plain>Genotyping </plain></SENT>
</text></title><p><text><SENT sid="74" pm="."><plain>Collection of saliva and extraction of genomic DNA was done using OrageneDNA sample collection kit (DNA Genotech Inc. </plain></SENT>
<SENT sid="75" pm="."><plain>Kanata, Ontario, Canada) according to the manufacturer’s instructions. </plain></SENT>
<SENT sid="76" pm="."><plain>To determine the length of the polymorphic promoter region of the 5-HTT, the DNA sequence was first amplified by polymerase chain reaction (PCR) and then separated by gel electrophoresis. </plain></SENT>
<SENT sid="77" pm="."><plain>PCR was carried out in a total volume of 25 μl containing ~60 ng of genomic template, 6.25 pmol of each primer and 1x Taq DNA Polymerase Master Mix (VWR international, Dublin, Ireland). </plain></SENT>
<SENT sid="78" pm="."><plain>The forward primer sequence was 5’–GGCGT TGCCG CTCTG AATGC- 3’ and the reverse primer sequence was 5’–GAGGG ACTGA GCTGG ACAAC CAC- 3’ (DNA technology A/S, Risskov, Denmark). </plain></SENT>
<SENT sid="79" pm="."><plain>Samples were amplified on a Perkin Elmer GeneAmp PCR 2400 system following an initial denaturing step for 3 min at 95°C. </plain></SENT>
<SENT sid="80" pm="."><plain>The amplification consisted of 40 cycles including denaturing at 95°C for 40 s, annealing at 60°C for 20 s and elongation at 72°C for 80 s, as previously described in. </plain></SENT>
<SENT sid="81" pm="."><plain>The described PCR yielded a long (529 bp) and a shorter (486 bp) fragment [19]. </plain></SENT>
<SENT sid="82" pm="."><plain>After four hours separation at 100 V on a 2.5% agarose gel (MetaPhor Agarose, Lonza cologne GmbH, Cologne, Germany), GelRed dye was added and the fragments were visualized by UV light (Biotium Inc, California, USA). </plain></SENT>
<SENT sid="83" pm="."><plain>The PCR 100 bp low ladder (Sigma-Aldrich CO, St. Louis, Mo, USA) was used to determine the length of the fragments. </plain></SENT>
</text></p><p><text><SENT sid="84" pm="."><plain>SNP genotyping was carried out using custom TaqMan SNP genotyping assays (Applied Biosystems, Foster City, CA, USA). </plain></SENT>
<SENT sid="85" pm="."><plain>Approximately 10 ng genomic DNA was amplified in a 5 μl reaction mixture in a 384-well plate containing 1x TaqMan genotyping master mix (Applied Biosystems) and 1x assay mix, the latter containing the respective primers and probes. </plain></SENT>
<SENT sid="86" pm="."><plain>The probes were labelled with the reporter dye FAM or VIC to distinguish between the two alleles. </plain></SENT>
<SENT sid="87" pm="."><plain>Approximately 10% of the samples were re-genotyped and the concordance rate was 100% (for more technical details see Olsen et al 2012 [20]). </plain></SENT>
</text></p></sec><sec id="sec007"><title><text><SENT sid="88" pm="."><plain>Data analysis and statistics </plain></SENT>
</text></title><p><text><SENT sid="89" pm="."><plain>The data are shown by means ± SEM. </plain></SENT>
<SENT sid="90" pm="."><plain>The 5-HTT mRNA in blood of the patients, the distribution of the 5-HTT genotype among patients versus healthy controls and characteristics of the patients grouped by genotype, were examined by linear regression, Pearson Chi-square and/or Student’s t-test. </plain></SENT>
<SENT sid="91" pm="."><plain>The main outcomes; i.e. number of steps and FDI measurements over time were compared regarding genotype by repeated measures ANOVA, between-subjects effect. </plain></SENT>
<SENT sid="92" pm="."><plain>Missing data at first or second follow-up were replaced by individual data from inclusion or previous follow-up, respectively. </plain></SENT>
<SENT sid="93" pm="."><plain>When sphericity assumption was not met, a Greenhouse-Geisser correction was applied. </plain></SENT>
<SENT sid="94" pm="."><plain>Separate analyses were performed to check for potential effects of covariates age, gender, Body Mass index (BMI) and treatment (covariates with p≤0.1 were kept in the final model). </plain></SENT>
<SENT sid="95" pm="."><plain>Fisher’s LSD post hoc tests using Bonferroni correction were applied to analyze the genotype stratified data at each time point. </plain></SENT>
<SENT sid="96" pm="."><plain>Statistical analyses were performed using SPSS version 21. </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="RESULTS"><sec sec-type="results" id="sec008"><title><text><SENT sid="97" pm="."><plain>Results </plain></SENT>
</text></title><p><text><SENT sid="98" pm="."><plain>In total 86 females and 34 males with CFS were included in the present study. </plain></SENT>
<SENT sid="99" pm="."><plain>As expected, the patients were less active than the 38 individuals in the matched control group (patients; 4662 ± 220 number of steps per day and 23 ± 0,84 in FDI score; controls 11293 ± 603 number of steps per day and 1.3 ± 0.46 in FDI score). </plain></SENT>
<SENT sid="100" pm="."><plain>A weak association between the predicted transcription rates and the 5-HTT mRNA expression in blood in the CFS patients (linear regression; beta = 0.10, p = 0.045) was observed (Fig 1A, 1B and 1C). </plain></SENT>
</text></p><SecTag type="FIG"><fig id="pone.0140883.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0140883.g001</object-id><label>Fig 1</label><caption><title><text><SENT sid="101" pm="."><plain>Role of polymorphisms in the 5-HTT promotor region. </plain></SENT>
</text></title><p><text><SENT sid="102" pm="."><plain>A) The 5-HTT short (S) allele consists of 14 repeats at 22 bp while the long (L) allele consists of 16 repeats and a possible A to G SNP. </plain></SENT>
<SENT sid="103" pm="."><plain>AP2 is a transcription inhibitor found to bind the sequence if a G substitution is present [5]. B) Five possible allele combinations ranged by their predicted rate of transcription. </plain></SENT>
<SENT sid="104" pm="."><plain>Frequency of the allele combinations in the Caucasian population: SS: 20%, SLG: 4%, LALG: 5%, SLA: 41% and LALA: 26% [6]. </plain></SENT>
<SENT sid="105" pm="."><plain>A: adenosine, G: guanosine, AP2: activating enhancer-binding protein. C) 5-HTT mRNA in blood in the CFS patients. </plain></SENT>
</text></p></caption><graphic xlink:href="pone.0140883.g001"/></fig></SecTag><p><text><SENT sid="106" pm="."><plain>At inclusion the 31 patients with the SS or SLG genotype had a lower number of steps per day and a higher FDI score than the 89 patients with the LALG, SLA or LALA genotype (Fig 2A and 2B). </plain></SENT>
<SENT sid="107" pm="."><plain>No genotype effects were observed in the healthy controls (Fig 2C and 2D). </plain></SENT>
<SENT sid="108" pm="."><plain>Moreover, the frequency of the SS or SLG genotype was not significantly higher in the patients than in the healthy controls; p = 0.55 (Table 1). </plain></SENT>
</text></p><SecTag type="FIG"><fig id="pone.0140883.g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0140883.g002</object-id><label>Fig 2</label><caption><title><text><SENT sid="109" pm="."><plain>Daily activity and disability scores in 5-HTT genotype stratified data; SS, SLG, LALG, SLA and LALA. </plain></SENT>
</text></title><p><text><SENT sid="110" pm="."><plain>A and B) Mean number of steps per day and Functional Disability Inventory (FDI) score in the patients at the time of inclusion. C and D) Mean number of steps per day and Functional Disability Inventory (FDI) score in the reference group i.e. healthy control subjects. </plain></SENT>
<SENT sid="111" pm="."><plain>Data are given as means ± SEM (Student’s t-test, SS+SLG versus LALG+SLA+LALA *p&lt;0.05). </plain></SENT>
</text></p></caption><graphic xlink:href="pone.0140883.g002"/></fig></SecTag><SecTag type="TABLE"><table-wrap id="pone.0140883.t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0140883.t001</object-id><label>Table 1</label><caption><title><text><SENT sid="112" pm="."><plain>Patients versus healthy controls; 5-HTT genotype distribution. </plain></SENT>
</text></title></caption><alternatives><graphic id="pone.0140883.t001g" xlink:href="pone.0140883.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"><text><SENT sid="113" pm="."><plain>SS/SLG </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="114" pm="."><plain>LALG/SLA/LALA </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="115" pm="."><plain>p-value a  </plain></SENT>
</text></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="116" pm="."><plain>Patients (%) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="117" pm="."><plain>31(26) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="118" pm="."><plain>89(74) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="119" pm="."><plain>0.55 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="120" pm="."><plain>Controls (%) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="121" pm="."><plain>8(21) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="122" pm="."><plain>30(79) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"/></tr></tbody></table></alternatives><table-wrap-foot><fn id="t001fn001"><p><text><SENT sid="123" pm="."><plain>a Pearson Chi-square test </plain></SENT>
</text></p></fn></table-wrap-foot></table-wrap></SecTag><p><text><SENT sid="124" pm="."><plain>Among the potential covariates gender, age, BMI and treatment, gender–the only covariate with p≤0.1 (Table 2)–was included as a covariate in the further analyses. </plain></SENT>
<SENT sid="125" pm="."><plain>Thus, the over-representation of females with the SS or SLG genotype was corrected for. </plain></SENT>
<SENT sid="126" pm="."><plain>Notably, 26 of 86 females, but only 5 of 34 males were SS or SLG carriers (Table 3). </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="pone.0140883.t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0140883.t002</object-id><label>Table 2</label><caption><title><text><SENT sid="127" pm="."><plain>Covariates considered in the analyses. </plain></SENT>
</text></title><p><text><SENT sid="128" pm="."><plain>Repeated measures ANOVA. </plain></SENT>
</text></p></caption><alternatives><graphic id="pone.0140883.t002g" xlink:href="pone.0140883.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1"><text><SENT sid="129" pm="."><plain>Outcome measure </plain></SENT>
</text></th><th align="left" rowspan="1" colspan="1"><text><SENT sid="130" pm="."><plain>Covariates </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="131" pm="."><plain>Within subjects effects. </plain></SENT>
<SENT sid="132" pm="."><plain>p-values </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="133" pm="."><plain>Between subjects effects. p-values </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="134" pm="."><plain>Included in final model. yes/no </plain></SENT>
</text></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="135" pm="."><plain>Number of steps </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="136" pm="."><plain>Age </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="137" pm="."><plain>0.152 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="138" pm="."><plain>0.419 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="139" pm="."><plain>No </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="140" pm="."><plain>Gender </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="141" pm="."><plain>0.357 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="142" pm="."><plain>0.019 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="143" pm="."><plain>Yes </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="144" pm="."><plain>BMI </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="145" pm="."><plain>0.650 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="146" pm="."><plain>0.391 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="147" pm="."><plain>No </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="148" pm="."><plain>Clonidine treatment </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="149" pm="."><plain>0.352 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="150" pm="."><plain>0.120 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="151" pm="."><plain>No </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="152" pm="."><plain>FDI </plain></SENT>
</text></td><td align="left" rowspan="1" colspan="1"><text><SENT sid="153" pm="."><plain>Age </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="154" pm="."><plain>0.071 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="155" pm="."><plain>0.707 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="156" pm="."><plain>No </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="157" pm="."><plain>Gender </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="158" pm="."><plain>0.037 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="159" pm="."><plain>0.072 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="160" pm="."><plain>Yes </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="161" pm="."><plain>BMI </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="162" pm="."><plain>0.477 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="163" pm="."><plain>0.615 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="164" pm="."><plain>No </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><text><SENT sid="165" pm="."><plain>Clonidine treatment </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="166" pm="."><plain>0.633 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="167" pm="."><plain>0.118 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="168" pm="."><plain>No </plain></SENT>
</text></td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t002fn001"><p><text><SENT sid="169" pm="."><plain>The table gives an overview of the association between covariates and the two outcome measures: Number of steps and Functional disability inventory (FDI). </plain></SENT>
<SENT sid="170" pm="."><plain>Covariates with a value p ≤ 0.1 were included in the final model. </plain></SENT>
</text></p></fn></table-wrap-foot></table-wrap></SecTag><SecTag type="TABLE"><table-wrap id="pone.0140883.t003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0140883.t003</object-id><label>Table 3</label><caption><title><text><SENT sid="171" pm="."><plain>Characteristics of patients grouped by genotype; 5-HTT SS/SLG versus 5-HTT LALG/SLA/LALA. </plain></SENT>
</text></title></caption><alternatives><graphic id="pone.0140883.t003g" xlink:href="pone.0140883.t003"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"><text><SENT sid="172" pm="."><plain>5-HTT SS/SLG n = 31 </plain></SENT>
</text></th><th align="left" rowspan="1" colspan="1"><text><SENT sid="173" pm="."><plain>5-HTT LALG/SLA/LALA n = 89 </plain></SENT>
</text></th><th align="left" rowspan="1" colspan="1"><text><SENT sid="174" pm="."><plain>p-values </plain></SENT>
</text></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="175" pm="."><plain>Gender, men/women (%) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="176" pm="."><plain>5/26 (0.16/0.84) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="177" pm="."><plain>29/60 (0.33/0.67) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="178" pm="."><plain>0.080 a  </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="179" pm="."><plain>Mean age (min/max) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="180" pm="."><plain>15.5 (12.8–17.9) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="181" pm="."><plain>15.3 (12.0–17.9) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="182" pm="."><plain>0.521 b  </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="183" pm="."><plain>Mean BMI (min/max) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="184" pm="."><plain>20.7 (16–32.3) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="185" pm="."><plain>21.2 (14.3–34.1) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="186" pm="."><plain>0.199 b  </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="187" pm="."><plain>Clonidine treatment yes/no (%) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="188" pm="."><plain>15/16 (0.48/0.52) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="189" pm="."><plain>45/44 (0.51/0.49) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="190" pm="."><plain>0.835 a  </plain></SENT>
</text></td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t003fn001"><p><text><SENT sid="191" pm="."><plain>aPearson Chi-square test </plain></SENT>
</text></p></fn><fn id="t003fn002"><p><text><SENT sid="192" pm="."><plain>bUnpaired student’s t-test. </plain></SENT>
</text></p></fn></table-wrap-foot></table-wrap></SecTag><p><text><SENT sid="193" pm="."><plain>At inclusion, 8 weeks and 30 weeks, a clear difference between the 5-HTT SS or SLG genotype versus the 5-HTT LALG, SLA or LALA genotype was observed (Fig 3A and 3B). </plain></SENT>
<SENT sid="194" pm="."><plain>Patients with the SS or SLG genotype had a significantly lower number of steps per day and also a significantly higher FDI score than patients with the LALG, SLA or LALA genotype when gender was taken into account as a covariate (repeated measures ANOVA, between-subjects effect, steps per day F(1,116) = 7.23, p = 0.008; FDI score F(1,115) = 7.81; p = 0.006). </plain></SENT>
</text></p><SecTag type="FIG"><fig id="pone.0140883.g003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0140883.g003</object-id><label>Fig 3</label><caption><title><text><SENT sid="195" pm="."><plain>The time course for outcome measures grouped as 5-HTT SS+SLG genotype, and 5-HTT LALG+SLA+LALA genotype following inclusion. </plain></SENT>
</text></title><p><text><SENT sid="196" pm="."><plain>A) Number of steps (repeated measure ANOVA, F(1,116) = 7.23, p = 0.008). B) Functional disability inventory, FDI (repeated measure ANOVA, F(1,115) = 7.81; p = 0.006). </plain></SENT>
<SENT sid="197" pm="."><plain>Data are given as means ± SEM (Fisher’s LSD post hoc test using Bonferroni correction *p&lt;0.05; **p&lt;0.01.) </plain></SENT>
</text></p></caption><graphic xlink:href="pone.0140883.g003"/></fig></SecTag><p><text><SENT sid="198" pm="."><plain>Additional analyses of the data at inclusion, 8 weeks and 30 weeks from only the 86 females, without the 34 males, gave the same results. </plain></SENT>
<SENT sid="199" pm="."><plain>Female patients with the SS or SLG genotype had a significantly lower number of steps per day and also a significantly higher FDI score than female patients with the LALG, SLA or LALA genotype (repeated measures ANOVA, females only, between-subjects effect, steps per day F(1,83) = 9.73; p = 0.002; FDI score F(1,82) = 9.29; p = 0.003). </plain></SENT>
</text></p></sec></SecTag><SecTag type="DISCUSS"><sec sec-type="conclusions" id="sec009"><title><text><SENT sid="200" pm="."><plain>Discussion </plain></SENT>
</text></title><p><text><SENT sid="201" pm="."><plain>The purpose of the present study was to examine how the 5-HTTLPR and SNP rs25531 A &gt; G genotype influences CFS. </plain></SENT>
<SENT sid="202" pm="."><plain>In accordance with previous studies of Caucasians or European Americans indicating a general 5-HTT SS or SLG genotype frequency of about 25% [6,10], the same genotype frequency was 26% in the patients and 21% in the controls. </plain></SENT>
<SENT sid="203" pm="."><plain>Thus, the 5-HTT genotype cannot explain why some individuals develop CFS. </plain></SENT>
<SENT sid="204" pm="."><plain>Interestingly however, we found that CFS patients with the 5-HTT SS or SLG genotype had a more pronounced reduction in physical and psychosocial functioning than patients with the 5-HTT LALG, SLA or LALA genotype. </plain></SENT>
<SENT sid="205" pm="."><plain>This suggests that patients with the 5-HTT SS or SLG genotype have a less favorable 30 weeks outcome than patients with the 5-HTT LALG, SLA or LALA genotype. </plain></SENT>
</text></p><p><text><SENT sid="206" pm="."><plain>Earlier in-vitro studies–as well as the present analyses of 5-HTT expression in blood–suggest that the transcription rate in Caucasians of the 5-HTT gene SLC6A4 may increase in the following order; SS, SLG, LALG, SLA and LALA [5]. </plain></SENT>
<SENT sid="207" pm="."><plain>Moreover, earlier in-vivo positron emission tomography studies have provided evidence that the SS and SLG subjects may display decreased expression of 5-HTT in the midbrain [21]. </plain></SENT>
<SENT sid="208" pm="."><plain>The result is a reduced 5-HT re-uptake, and a higher concentration of extracellular serotonin. </plain></SENT>
<SENT sid="209" pm="."><plain>This might have two possible consequences: 1) either increased negative feedback as a result of more available 5-HT near the presynaptic autoreceptors, or 2) increased signaling because of a higher concentration of 5-HT near the postsynaptic receptors of the cell membrane. </plain></SENT>
</text></p><p><text><SENT sid="210" pm="."><plain>Depending on the localization of the 5-HTT relative to the 5-HT autoreceptors, this might decrease or increase the 5-HT signaling in the CNS. </plain></SENT>
<SENT sid="211" pm="."><plain>Hence, genetic variability in the gene encoding the 5-HTT has consequences that may be associated with mental health. </plain></SENT>
<SENT sid="212" pm="."><plain>Previous data have demonstrated that the S allele of the 5-HTTLPR may be linked to depression [22,23] and suicidality in relation to stressful life events [22]. </plain></SENT>
<SENT sid="213" pm="."><plain>Earlier studies also suggest that the S allele of the 5-HTTLPR is associated with neurocognitive impairment [24] and bipolar disorders [25]. </plain></SENT>
</text></p><p><text><SENT sid="214" pm="."><plain>In addition, variation in the 5-HTT gene SLC6A4 may modulate attention to threat [26], anxiety, negative affect and fear [10–12]. </plain></SENT>
<SENT sid="215" pm="."><plain>Moreover, the SS and SLG genotype seems to be associated with higher neuroticism [11], and a more serious symptomatic profile in patients who suffers from posttraumatic stress disorders [10]. </plain></SENT>
<SENT sid="216" pm="."><plain>Ultimately, it has also been suggested that the 5-HTT SS and SLG genotype may be associated with increased neuroplasticity making individuals more susceptible to environmental influences [13]. </plain></SENT>
<SENT sid="217" pm="."><plain>Hence, psychosocial aspects, bullying and stressful life events may have a more pronounced impact on adolescents with the 5-HTT SS and SLG genotype than other individuals. </plain></SENT>
<SENT sid="218" pm="."><plain>These data, together with the observations of the present study, indicate that the 5-HTT SS and SLG genotype may be a factor that contributes to the maintenance of CFS. </plain></SENT>
</text></p><p><text><SENT sid="219" pm="."><plain>Genetic variability that affect the re-uptake of 5-HT may also be important for the regulation of the hypothalamic-pituitary-adrenal (HPA) axis [27], which in turn can affect the symptom burden [28]. </plain></SENT>
<SENT sid="220" pm="."><plain>Earlier findings show that young CFS patients seem to have an increased efferent sympathetic nerve activity that stimulate the adrenal medulla and increase the secretion of noradrenaline/adrenaline [29]. </plain></SENT>
<SENT sid="221" pm="."><plain>Moreover, previous data have demonstrated that CFS patients often have an attenuation of the HPA-axis, which involves a reduced release of both ACTH and cortisol during psychosocial stress [30]. </plain></SENT>
<SENT sid="222" pm="."><plain>In addition, CFS patients may have changes in the hormonal systems controlling blood volume and osmolality [31]. </plain></SENT>
<SENT sid="223" pm="."><plain>This supports the theory that functional changes in the brainstem may be a part of the etiology in CFS. </plain></SENT>
</text></p><p><text><SENT sid="224" pm="."><plain>An increasing number of studies suggest that changes in the central nervous system are important for CFS, including abnormalities in the serotonergic system and disturbed control of the HPA axis [30]. </plain></SENT>
<SENT sid="225" pm="."><plain>In line with this hypothesis, our study indicates that individual characteristics of the serotonergic system due to 5-HTTLPR S allele and the SNP rs25231 A &gt; G, important for the expression of the 5-HTT in the midbrain [21], might contribute to maintenance of CFS. </plain></SENT>
<SENT sid="226" pm="."><plain>However, the frequency of the 5-HTT SS and SLG genotype do not increase the risk of CFS outbreak. </plain></SENT>
<SENT sid="227" pm="."><plain>Hence we think that the 5-HTT SS and SLG genotype rather may be associated with increased susceptibility to negative environmental influences, inactivity and social isolation. </plain></SENT>
</text></p><p><text><SENT sid="228" pm="."><plain>In conclusion, our data demonstrate that the 5-HTT genotype is associated with daily activity and disability score in young CFS patients. </plain></SENT>
<SENT sid="229" pm="."><plain>Clearly, CFS patients with the 5-HTT SS or SLG genotype had a worse 30 weeks outcome than CFS patients with the 5-HTT LALG, SLA or LALA genotype. </plain></SENT>
<SENT sid="230" pm="."><plain>The present study suggests that the 5-HTT genotype may be a factor that contributes to maintenance of CFS. </plain></SENT>
</text></p></sec></SecTag></body><back><SecTag type="ACK_FUND"><ack><p><text4fund><text><SENT sid="231" pm="."><plain>We thank Ada Ingvaldsen for excellent technical support. </plain></SENT>
</text></text4fund></p></ack></SecTag><SecTag type="REF"><ref-list><title>References</title><ref id="pone.0140883.ref001"><text><SENT sid="232" pm="."><plain>1 FukudaK, StrausSE, HickieI, SharpeMC, DobbinsJG, KomaroffA (1994) The chronic fatigue syndrome: a comprehensive approach to its definition and study. </plain></SENT>
<SENT sid="233" pm="."><plain>International Chronic Fatigue Syndrome Study Group. Ann Intern Med 121: 953–959. <?supplied-pmid 7978722?>7978722 </plain></SENT>
</text></ref><ref id="pone.0140883.ref002"><text><SENT sid="234" pm="."><plain>2 FarmerA, FowlerT, ScourfieldJ, ThaparA (2004) Prevalence of chronic disabling fatigue in children and adolescents. Br J Psychiatry 184: 477–481. <?supplied-pmid 15172940?>15172940 </plain></SENT>
</text></ref><ref id="pone.0140883.ref003"><text><SENT sid="235" pm="."><plain>3 GoertzelBN, PennachinC, de SouzaCoelho L, GurbaxaniB, MaloneyEM, JonesJF (2006) Combinations of single nucleotide polymorphisms in neuroendocrine effector and receptor genes predict chronic fatigue syndrome. Pharmacogenomics 7: 475–483. <?supplied-pmid 16610957?>16610957 </plain></SENT>
</text></ref><ref id="pone.0140883.ref004"><text><SENT sid="236" pm="."><plain>4 SmithAK, DimulescuI, FalkenbergVR, NarasimhanS, HeimC, VernonSD, et al (2008) Genetic evaluation of the serotonergic system in chronic fatigue syndrome. Psychoneuroendocrinology 33: 188–197. <?supplied-pmid 18079067?>18079067 </plain></SENT>
</text></ref><ref id="pone.0140883.ref005"><text><SENT sid="237" pm="."><plain>5 HuXZ, LipskyRH, ZhuG, AkhtarLA, TaubmanJ, GreenbergBD, et al (2006) Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder. Am J Hum Genet 78: 815–826. <?supplied-pmid 16642437?>16642437 </plain></SENT>
</text></ref><ref id="pone.0140883.ref006"><text><SENT sid="238" pm="."><plain>6 NakamuraM, UenoS, SanoA, TanabeH (2000) The human serotonin transporter gene linked polymorphism (5-HTTLPR) shows ten novel allelic variants. Mol Psychiatry 5: 32–38. <?supplied-pmid 10673766?>10673766 </plain></SENT>
</text></ref><ref id="pone.0140883.ref007"><text><SENT sid="239" pm="."><plain>7 LeschKP, BengelD, HeilsA, SabolSZ, GreenbergBD, PetriS, et al (1996) Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 274: 1527–1531. <?supplied-pmid 8929413?>8929413 </plain></SENT>
</text></ref><ref id="pone.0140883.ref008"><text><SENT sid="240" pm="."><plain>8 HeilsA, TeufelA, PetriS, StoberG, RiedererP, BengelD, et al (1996) Allelic variation of human serotonin transporter gene expression. J Neurochem 66: 2621–2624. <?supplied-pmid 8632190?>8632190 </plain></SENT>
</text></ref><ref id="pone.0140883.ref009"><text><SENT sid="241" pm="."><plain>9 JiangJG, DeFrancesMC, MachenJ, JohnsonC, ZarnegarR (2000) The repressive function of AP2 transcription factor on the hepatocyte growth factor gene promoter. Biochem Biophys Res Commun 272: 882–886. <?supplied-pmid 10860846?>10860846 </plain></SENT>
</text></ref><ref id="pone.0140883.ref010"><text><SENT sid="242" pm="."><plain>10 XieP, KranzlerHR, PolingJ, SteinMB, AntonRF, BradyK, et al (2009) Interactive effect of stressful life events and the serotonin transporter 5-HTTLPR genotype on posttraumatic stress disorder diagnosis in 2 independent populations. Arch Gen Psychiatry 66: 1201–1209. 10.1001/archgenpsychiatry.2009.153 <?supplied-pmid 19884608?>19884608 </plain></SENT>
</text></ref><ref id="pone.0140883.ref011"><text><SENT sid="243" pm="."><plain>11 LonsdorfTB, RuckC, BergstromJ, AnderssonG, OhmanA, SchallingM, et al (2009) The symptomatic profile of panic disorder is shaped by the 5-HTTLPR polymorphism. Prog Neuropsychopharmacol Biol Psychiatry 33: 1479–1483. 10.1016/j.pnpbp.2009.08.004 <?supplied-pmid 19683026?>19683026 </plain></SENT>
</text></ref><ref id="pone.0140883.ref012"><text><SENT sid="244" pm="."><plain>12 LonsdorfTB, WeikeAI, NikamoP, SchallingM, HammAO, OhmanA (2009) Genetic gating of human fear learning and extinction: possible implications for gene-environment interaction in anxiety disorder. Psychol Sci 20: 198–206. 10.1111/j.1467-9280.2009.02280.x <?supplied-pmid 19175757?>19175757 </plain></SENT>
</text></ref><ref id="pone.0140883.ref013"><text><SENT sid="245" pm="."><plain>13 BelskyJ, JonassaintC, PluessM, StantonM, BrummettB, WilliamsR (2009) Vulnerability genes or plasticity genes? Mol Psychiatry 14: 746–754. 10.1038/mp.2009.44 <?supplied-pmid 19455150?>19455150 </plain></SENT>
</text></ref><ref id="pone.0140883.ref014"><text><SENT sid="246" pm="."><plain>14 SulheimD, FagermoenE, WingerA, AndersenAM, GodangK, MullerF, et al (2014) Disease Mechanisms and Clonidine Treatment in Adolescent Chronic Fatigue Syndrome: A Combined Cross-sectional and Randomized Clinical Trial. JAMA Pediatr. </plain></SENT>
</text></ref><ref id="pone.0140883.ref015"><text><SENT sid="247" pm="."><plain>15 SulheimD, HurumH, HellandIB, ThaulowE, WyllerVB (2012) Adolescent chronic fatigue syndrome; a follow-up study displays concurrent improvement of circulatory abnormalities and clinical symptoms. Biopsychosoc Med 6: 10 10.1186/1751-0759-6-10 <?supplied-pmid 22436201?>22436201 </plain></SENT>
</text></ref><ref id="pone.0140883.ref016"><text><SENT sid="248" pm="."><plain>16 MackoRF, HaeuberE, ShaughnessyM, ColemanKL, BooneDA, SmithGV, et al (2002) Microprocessor-based ambulatory activity monitoring in stroke patients. Med Sci Sports Exerc 34: 394–399. <?supplied-pmid 11880800?>11880800 </plain></SENT>
</text></ref><ref id="pone.0140883.ref017"><text><SENT sid="249" pm="."><plain>17 WardDS, EvensonKR, VaughnA, RodgersAB, TroianoRP (2005) Accelerometer use in physical activity: best practices and research recommendations. Med Sci Sports Exerc 37: S582–588. <?supplied-pmid 16294121?>16294121 </plain></SENT>
</text></ref><ref id="pone.0140883.ref018"><text><SENT sid="250" pm="."><plain>18 WalkerLS, GreeneJW (1991) The functional disability inventory: measuring a neglected dimension of child health status. J Pediatr Psychol 16: 39–58. <?supplied-pmid 1826329?>1826329 </plain></SENT>
</text></ref><ref id="pone.0140883.ref019"><text><SENT sid="251" pm="."><plain>19 MatreD, OlsenMB, JacobsenLM, KleinT, GjerstadJ (2013) Induction of the perceptual correlate of human long-term potentiation (LTP) is associated with the 5-HTT genotype. Brain Res 1491: 54–59. 10.1016/j.brainres.2012.10.045 <?supplied-pmid 23123704?>23123704 </plain></SENT>
</text></ref><ref id="pone.0140883.ref020"><text><SENT sid="252" pm="."><plain>20 OlsenMB, JacobsenLM, SchistadEI, PedersenLM, RyghLJ, RoeC, et al (2012) Pain intensity the first year after lumbar disc herniation is associated with the A118G polymorphism in the opioid receptor mu 1 gene: evidence of a sex and genotype interaction. J Neurosci 32: 9831–9834. 10.1523/JNEUROSCI.1742-12.2012 <?supplied-pmid 22815498?>22815498 </plain></SENT>
</text></ref><ref id="pone.0140883.ref021"><text><SENT sid="253" pm="."><plain>21 ReimoldM, SmolkaMN, SchumannG, ZimmerA, WraseJ, MannK, et al (2007) Midbrain serotonin transporter binding potential measured with [11C]DASB is affected by serotonin transporter genotype. J Neural Transm 114: 635–639. <?supplied-pmid 17225932?>17225932 </plain></SENT>
</text></ref><ref id="pone.0140883.ref022"><text><SENT sid="254" pm="."><plain>22 CaspiA, SugdenK, MoffittTE, TaylorA, CraigIW, HarringtonH, et al (2003) Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 301: 386–389. <?supplied-pmid 12869766?>12869766 </plain></SENT>
</text></ref><ref id="pone.0140883.ref023"><text><SENT sid="255" pm="."><plain>23 KiyoharaC, YoshimasuK (2010) Association between major depressive disorder and a functional polymorphism of the 5-hydroxytryptamine (serotonin) transporter gene: a meta-analysis. Psychiatr Genet 20: 49–58. 10.1097/YPG.0b013e328335112b <?supplied-pmid 20016401?>20016401 </plain></SENT>
</text></ref><ref id="pone.0140883.ref024"><text><SENT sid="256" pm="."><plain>24 KalskaH, PesonenU, LehikoinenS, StenbergJH, LipsanenJ, Niemi-PynttariJ, et al (2013) Association between Neurocognitive Impairment and the Short Allele of the 5-HTT Promoter Polymorphism in Depression: A Pilot Study. </plain></SENT>
<SENT sid="257" pm="."><plain>Psychiatry J 2013: 849346 10.1155/2013/849346 <?supplied-pmid 24286069?>24286069 </plain></SENT>
</text></ref><ref id="pone.0140883.ref025"><text><SENT sid="258" pm="."><plain>25 JiangHY, QiaoF, XuXF, YangY, BaiY, JiangLL (2013) Meta-analysis confirms a functional polymorphism (5-HTTLPR) in the serotonin transporter gene conferring risk of bipolar disorder in European populations. Neurosci Lett 549: 191–196. 10.1016/j.neulet.2013.05.065 <?supplied-pmid 23756178?>23756178 </plain></SENT>
</text></ref><ref id="pone.0140883.ref026"><text><SENT sid="259" pm="."><plain>26 OsinskyR, ReuterM, KupperY, SchmitzA, KozyraE, AlexanderN, et al (2008) Variation in the serotonin transporter gene modulates selective attention to threat. Emotion 8: 584–588. 10.1037/a0012826 <?supplied-pmid 18729589?>18729589 </plain></SENT>
</text></ref><ref id="pone.0140883.ref027"><text><SENT sid="260" pm="."><plain>27 van der DoelenRH, DeschampsW, D'AnnibaleC, PeetersD, WeversRA, ZelenaD, et al (2014) Early life adversity and serotonin transporter gene variation interact at the level of the adrenal gland to affect the adult hypothalamo-pituitary-adrenal axis. Transl Psychiatry 4: e409 10.1038/tp.2014.57 <?supplied-pmid 25004389?>25004389 </plain></SENT>
</text></ref><ref id="pone.0140883.ref028"><text><SENT sid="261" pm="."><plain>28 CroffordLJ, YoungEA, EnglebergNC, KorszunA, BruckschCB, McClureLA, et al (2004) Basal circadian and pulsatile ACTH and cortisol secretion in patients with fibromyalgia and/or chronic fatigue syndrome. Brain Behav Immun 18: 314–325. <?supplied-pmid 15157948?>15157948 </plain></SENT>
</text></ref><ref id="pone.0140883.ref029"><text><SENT sid="262" pm="."><plain>29 WyllerVB, SaulJP, AmlieJP, ThaulowE (2007) Sympathetic predominance of cardiovascular regulation during mild orthostatic stress in adolescents with chronic fatigue. Clin Physiol Funct Imaging 27: 231–238. <?supplied-pmid 17564672?>17564672 </plain></SENT>
</text></ref><ref id="pone.0140883.ref030"><text><SENT sid="263" pm="."><plain>30 SegalTY, HindmarshPC, VinerRM (2005) Disturbed adrenal function in adolescents with chronic fatigue syndrome. J Pediatr Endocrinol Metab 18: 295–301. <?supplied-pmid 15813608?>15813608 </plain></SENT>
</text></ref><ref id="pone.0140883.ref031"><text><SENT sid="264" pm="."><plain>31 WyllerVB, EvangJA, GodangK, SolhjellKK, BollerslevJ (2010) Hormonal alterations in adolescent chronic fatigue syndrome. Acta Paediatr 99: 770–773. 10.1111/j.1651-2227.2010.01701.x <?supplied-pmid 20199497?>20199497 </plain></SENT>
</text></ref></ref-list></SecTag></back></article>
